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Abstract
The relationship between abnormal HER2 expression and cancer is important in cancer therapeutics. Formation and spread of
cancer cells may be restricted by inhibiting HER2. We conducted ligand-based and structure-based studies to assess the
potency of natural compounds as potential HER2 inhibitors. Multiple linear regression (MLR) and support vector machine (SVM)
models were constructed to predict biological activities of natural compounds, and molecular dynamics (MD) was used to
assess their stability with HER2 under a dynamic environment. Predicted bioactivities of the natural compounds ranged from
6.014–9.077 using MLR (r
2=0.7954) and 5.122–6.950 using SVM (r
2=0.8620). Both models were in agreement and suggest
bioactivitybased oncandidate structure. Conformation changes caused byMDfavored the formation of stabilizingH-bonds. All
candidates had higher stability than Lapinatib, which may be due to the number and spatial distribution of additional H-bonds
and hydrophobic interactions. Amino acids Lys724 and Lys736 are critical for binding in HER2, and Thr798, Cys805, and Asp808
are also important for increased stability. Candidates may block the entrance to the ATP binding site located within the inner
regions and prevent downstream activation of HER2. Our multidirectional approach indicates thatthe natural compounds have
good ligand efficacy in addition to stable binding affinities to HER2, and should be potent candidates of HER2 inhibitors. With
regard to drug design, designing HER2 inhibitors with carboxyl or carbonyl groups available for H-bond formation with Lys724
and Lys736, and benzene groups for hydrophobic contact with Cys805 may improve protein-ligand stability.
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Introduction
HER2 are members of the epidermal growth factor receptor
tyrosine kinase protein family which includes HER1/EGFR,
HER2/ErbB2, HER3/ErbB3, and ErbB4. These proteins form
various homo- and hetero- dimer receptors on human cell
membranes. When these receptors bind with ligands, autophos-
phorylation will occur and activate P13k/Akt and Ras/Raf
signaling pathways, stimulating signal transduction of downstream
cell growth and differentiation [1,2]. Clinically, abnormalities in
HER2 gene regulation will cause receptor over-production,
resulting in various cancers including breast cancer, ovarian
cancer, gastric cancer, and prostate cancer [3–7]. Therefore,
inhibiting HER2 expression and function is critical in treating
cancer and preventing the spread of cancerous cells.
Trastuzumab (HerceptinH) and Lapatinib (TykerbH) are two
drugs used clinically in breast cancer. Trastuzumab inhibits over-
expression of HER2 [8], and Lapatinib inhibits HER2 autophos-
phorylation by competing with ATP for the HER2 protein kinase
domain, thus preventing further signal transduction [9]. Drug
resistance issues have been reported for Trastuzumab [10].
Synergistic effects on breast cancer is observed when Lapatinib
is used with Capecitabine, but side effects such as nausea,
vomiting, and diarrhea have been recorded [11].
Computer-aided drug design is widely used in developing new
drugs and has been integrated in this laboratory with our self-
developed TCM Database@Taiwan [12] to design and develop
novel drugs from traditional Chinese medicine [13–17]. Much
research has proven that traditional Chinese herb compounds
exhibit antioxidation and anti-inflammation effects and have
therapeutic effects on cancer [18–20]. A preliminary experiment
conducted in this laboratory identified several natural compounds
from traditional Chinese herbs as HER2 inhibitors through
docking and 3D-QSAR evaluation [21]. However, as static state
docking does not necessarily equal stability in a dynamic state (ie.
body), further evaluation is required. This research aims to predict
biological activity with different statistical models, and evaluate
candidate-HER2 complex stability under a dynamic state.
Materials and Methods
Candidate Compounds and Docking Site
Based on our previous findings [21], natural compounds 2-O-
caffeoyl tartaric acid, 2-O-feruloyl tartaric acid, and salvianolic
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28793acid C exhibited good docking characteristics and were selected as
candidates for further investigation. Lapatinib was used as the
control. The HER2 docking site was constructed through
sequence homology and detailed elsewhere [21].
Biological Activity Prediction using Multiple Linear
Regression (MLR) and Support Vector Machine (SVM)
Models
A total of 298 HER2 ligands were adapted to construct activity
(pIC50) prediction models [22–35]. Descriptors of each ligand were
calculated using the Calculate Molecular Properties module in
Discovery Studio 2.5 (DS 2.5; Accelrys, San Diego, CA) and
pluggedintotheGeneticApproximation(GA)algorithm toselect12
optimum descriptors for predicting pIC50. The selected descriptors
were used to construct MLR and SVM models using Matlab
Statistics Toolbox and libSVM, respectively. Descriptors were
normalized between [21,+1]beforeSVMmodeltraining.Gaussian
radial basis function was selected as the kernel function for SVM
model generation. The HER2 ligands were randomly divided into a
238 ligand training set and a 60 ligand test set for validation.
Prediction results were validated with 5-fold cross validation. The
constructed models were applied to predict biological activities
(pIC50) of the control and top 3 natural compounds.
Molecular Dynamics (MD) Simulation
The HER2 protein structure used within this study was
constructed through homology modeling using EGFR kinase
domain structures found in Protein Data Bank (PDB: 2ITY and
2J5E). Modeling details and validity testing are detailed in our
previous study [21]. Molecular dynamics simulation was carried
out using DS 2.5 Standard Dynamics Cascade package with the
following settings: [minimization] steepest descent, [conjugate
gradient] maximum steps of 500, [heating time] 50 ps, [equili-
bration time] 200 ps, [total production time] 20 ns with NVT,
[constant temperature dynamics] Berendsen weak coupling
method, [temperature coupling decay time] 0.4 ps with the
Figure 1. Correlation of observed and predicted activity (pIC50) by different prediction models. (A) MLR and (B) SVM.
doi:10.1371/journal.pone.0028793.g001
Table 1. DockScore and predicted activities of candidate
compounds using MLR and SVM.
Compounds Dock Score
a MLR SVM
2-O-Caffeoyl tartaric acid 121.870 6.879 5.339
2-O-Feruloyl tartaric acid 121.483 6.014 5.122
Salvianolic acid C 104.833 9.077 6.950
Lapatinib* 67.330 7.640 7.058
a: scores adapted from Sun et al. [21].
*: control.
doi:10.1371/journal.pone.0028793.t001
Figure 2. Trajectory profiles of RMSD and total energy during
molecular dynamics simulation. (A) Complex RMSD, (B) ligand
RMSD, and (C) total energy.
doi:10.1371/journal.pone.0028793.g002
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28793Figure 3. Hydrogen bond distance (A ˚) of candidates during MD simulation. (A) Lapatinib, (B) 2-O-Caffeoyl tartaric acid, (C) 2-O-Feruloyl
tartaric acid, and (D) Salvianolic acid C.
doi:10.1371/journal.pone.0028793.g003
Figure 4. Structural scaffolds of candidate compounds. (A) Lapatinib, (B) 2-O-Caffeoyl tartaric acid, (C) 2-O-Feruloyl tartaric acid, and (D)
Salvianolic acid C. Locations of importance during MD are denoted by numbers.
doi:10.1371/journal.pone.0028793.g004
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310 K. Hydrogen bonds, distance of hydrogen bond, root mean
square deviations (RMSD) of complex, RMSD of ligand, total
energy of complex, and torsion angles were analyzed by the
analyze trajectory protocol of DS 2.5 following MD simulation.
Protein-ligand interactions were analyzed with the LIGPLOT
program [36].
Results and Discussion
Biological Activity Predictions using MLR and SVM
The following MLR model was generated utilizing the GA
descriptors and 238 training-set ligands:
E1~2:1339z0:092423|NumExplicitBondsz0:37231|NumRings6
{0:25576|NumStereoAtomsz0:19439|NumAtomClassesz0:30864
|NumH{Acceptors{0:014194|MolecularSurfaceArea
z1:5485|CHI3cz1:3483|CHI3F{0:40743|SC2
{2:7921|JursFPSA{zz0:066095|JursPPSA{s
{0:00094984|PMI X
Correlation of actual and predicted activities of HER2 ligands
based on the generated MLR are shown in Figure 1A and the
residual plot indicating the goodness-of-fit is shown in Figure S1.
Majority of the predicted values are within the 95% prediction
bands, indicating acceptable correlation of the MLR model
(r
2=0.7954). Similarly, the SVM model was generated using
identical GA descriptors and the results are illustrated in Figure 1B.
Acceptable correlation was also observed (r
2=0.8620). Based on
these results, the models are acceptable models for predicting
activity of HER2 ligands.
Table 1 summarizes the predicted biological activities for
Lapatinib and the candidate compounds using MLR and SVM
models. All compounds were predicted as biologically active and
are in agreement with 3D-QSAR results previously reported [21].
In contrast to descriptive bioactivity predictions based on 3D-
QSAR results, MLR and SVM predictions allow quantitative
predictions on the strength of bioactivity in each compound.
Salvianolic acid C showed the highest bioactivity among TCM
candidates.
Molecular Dynamics Simulation
Stability of Lapatinib and the TCM candidates were achieved
after 10 ns in a dynamic environment (Figure 2). The RMSD of
whole complexes was approximately 1.6 A ˚ (Figure 2A). The
smallest RMSD was observed in 2-O-caffeoyl tartaric acid (0.6 A ˚).
The RMSD of the other compounds were ca. 1.3 A ˚ (Figure 2B).
The small variation of 2-O-caffeoyl tartaric acid suggests a stable
state within the receptor site. Total energy trajectories indicate
that the candidates form complexes with lower energy compared
Figure 5. Binding pose of candidate compounds in HER2. (A) Lapatinib, (B) 2-O-Caffeoyl tartaric acid, (C) 2-O-Feruloyl tartaric acid, and (D)
Salvianolic acid C. Differences from the docking pose are specified by the red circle. Hydrogen-bond interactions (green dashed line), Pi interactions
(orange line). The three H atoms of Lys 724 amine subgroup are labeled as HZ1, HZ2, and HZ3.
doi:10.1371/journal.pone.0028793.g005
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the candidates as drug alternatives to Lapatinib.
The amine residue on Lys724 in HER2 protein is important to
form hydrogen bonds (H-bond) with ligands. Each ligand formed
at least one stable H-bond with Lys724 throughout the MD
simulation (Figure 3). The amine residue constantly rotates when
bound to Lapatinib. Overlapping of the indicator lines suggests the
existence of multiple H-bonds at Lys724 with 2-O-caffeoyl tartaric
acid after 10 ns. H-bonds with 2-O-feruloyl tartaric acid and
salvianolic acid C were fairly stable. Rotation was observed with
salvianolic acid C from 14–20 ns.
Stability mechanisms of each candidate can be provided by MD
simulation trajectories. For clarification purposes, specific locations
are denoted by Roman numerals and torsion angle locations are
designated by Arabic numerals in Figure 4. In Lapatinib, the bond
between Lys724 and the SO2 residue in docking was substituted by
the NH group (red circle) at the beginning of MD (Figure 5A,
S1A). The shift occurred because the bond between NH3
+-N is
stronger than that of NH3
+-SO2, and might have been triggered
by procedures (minimization, heating, and equilibration) prior to
MD production. During MD, Lapatinib formed stable H-bonds
with Lys724 and Leu726 at I, and a stable pi-cation interaction
with Lys753 at II (Figure 4A). Torsion angles indicate bonds 1–5
were stable, most likely due to the H-bond at I. Moieties II and III
were also important to the stability of Lapatinib. At approximately
0.16 ns, II rotated to being perpendicular to IV. The conforma-
tion change may have contributed to the decrease in total energy
by reducing strain on the connecting O atom. The rotation of III
to being perpendicular to V also coincided with the reduction of
total energy in Figure 2C.
Differences from docking were also observed for 2-O-caffeoyl
tartaric acid. Cys805-Asp808 formed a helix structure during
docking (Figure S2B). During MD, a fold in the original helix (red
circle, Figure 5B) enabled formation of stable H-bonds between
Asp808 and VI. In addition, 2-O-caffeoyl tartaric acid was
anchored to the binding site by multiple H-bonds formed through
VII and VIII with Lys724, VIII and IX with Lys736, and X with
Cys805. Similar to being locked-down, movement of the ligand was
limited except at XI. Additional evidence is provided by the small
torsion angles recorded for the backbone structure of 2-O-caffeoyl
tartaric acid. Changes in torsion were generally small, and notable
movement was only observed on hydroxyl side residues 6, 7, 13
(Figure 4B). These observations can explain the low ligand RMSD
(Figure 2B) and support the stability of the formed complex.
Figure 6. Protein-ligand interaction analysis by LIGPLOT. (A) Lapatinib, (B) 2-O-Caffeoyl tartaric acid, (C) 2-O-Feruloyl tartaric acid, and (D)
Salvianolic acid C.
doi:10.1371/journal.pone.0028793.g006
Figure 7. Centroid distance between candidates and proximate HER2 amino acids. (A) Lapatinib, (B) 2-O-Caffeoyl tartaric acid, (C) 2-O-
Feruloyl tartaric acid, and (D) Salvianolic acid C. Centroids of the ligands and amino acids are represented in yellow and green, respectively.
doi:10.1371/journal.pone.0028793.g007
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acid was observed during MD (Figure 5C, S1C). The rotation
flipped XII towards Lys736, and H-bonds were formed.
Additional H-bonds were formed at XIII with Lys724 and at
XIV with Cys805. All formed H-bonds were stable throughout
MD. Small torsion changes were observed for 2-O-feruloyl tartaric
acid except at 16 which was not restricted by any bond formation
(Figure 4C). The compact structure and the even distribution of
the H-bond formation locations may be the reason 2-O-feruloyl
tartaric acid has the highest stability (ie. lowest total energy) among
all the tested compounds (Figure 2C).
Conformational changes contributing to higher stability was
also observed in salvianolic acid C (Figure 5D, Figure S2D). The
benzene structure XV on salvianolic acid C torqued nearly 90
degrees during MD (red circle, Figure 5D), and the pi-interaction
originally observed during docking was lost. The rotation relocated
available residues to favorable H-bond forming locations, and H-
bonds were formed between XVI and Lys736 and XVII and
Thr798. The pi-cation interaction with Lys724 was replaced by
the H-bonds formed at XVIII with the three available H atoms
from Lys724. Small torsion angles (Figure 4D) provide evidence of
the ligand stability.
Hydrophobic interactions determined for each ligand at the end
of MD are illustrated in Figure 6. In addition to the previously
discussed H-bonds, Lapatinib was further stabilized through
hydrophobic interaction with Gly727, Val734, Ile752, Lys753,
and Leu807 (Figure 6A). Lys724 and Leu726 were important in
forming hydrophobic interactions with 2-O-caffeoyl tartaric acid
(Figure 6B) and 2-O-feruloyl tartaric acid (Figure 6C). An
additional hydrophobic interaction with Tyr803 was observed in
2-O-feruloyl tartaric acid. Eight amino acids were detected as
exhibiting hydrophobic interaction on Salvianolic acid C
(Figure 6D). Majority of the cyclic carbon moieties were stabilized
through these interactions.
The spatial location and distances of nearby amino acids with
the centroid of each candidate ligand are depicted in Figures 7 and
8. A bimodal distribution of amino acid distances was observed for
Lapatinib. On the other hand, the distance of nearby amino acids
from the centroid of the TCM candidates were more uniform. The
distance distribution (Figure 9) suggests that all test ligands were
tightly fitted within the binding site and can effectively block ATP
from binding. Furthermore, the candidates were more closely
bound to the binding site than Lapatinib, indicating another
advantage of the candidates as a potential Lapatinib substitute.
MD observations indicate that the candidate compounds are
more stable within the HER2 binding site than Lapatinib. The
stability could be explained in part by the multiple H-bonds
formed with the binding site. Conformational changes induced by
the MD simulation were favorable in forming additional H-bonds
that contributed to overall stability of the candidates.
Possibility of the natural compound candidates as alternatives to
Lapatinib was supported by the ligand based analysis and MD
simulation. Candidates were predicted as biologically active by the
constructed MLR (r
2=0.7954) and SVM (r
2=0.8620) models
based on their ligand characteristics. Molecular simulation
revealed that candidates formed more stable complexes with the
HER2 binding site (ie. lower in total energy) than Lapatinib. This
increased stability may be explained by the formation of additional
stabilizing H-bonds and hydrophobic contacts. Figure 10 summa-
rizes the key conclusions from the preliminary study [21] and this
current investigation. Amino acids that are critical for HER2-
ligand interaction include Lys724, Lys736, and Cys805. As
illustrated in Figure 10, binding at the key amino acids results in
blocking of the ATP binding site entrance, and may result in
inhibition of HER2 activity. Analysis of the candidates indicates
that carbonyl, carboxylic acid, and hydroxyl groups are critical
moieties for stable binding. Based on the results of this study, the
natural compound candidates have potential as biologically active
compounds with improved stability in HER2. Designing HER2
inhibitors with carbonyl, carboxyl, and hydroxyl groups available
for H-bond formation may improve protein-ligand stability.
Figure 8. Distribution of centroid distance (A ˚) between ligand
and proximate residues.
doi:10.1371/journal.pone.0028793.g008
Figure 9. Population of centroid distance (A ˚) between ligand
and proximate residues.
doi:10.1371/journal.pone.0028793.g009
HER2 Inhibitors from Natural Products Database
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28793Supporting Information
Figure S1 Residual plot indicating the goodness-of-fit
for the constructed MLR model.
(TIF)
Figure S2 Docking pose of TCM candidates in HER2. (A)
Lapatinib, (B) 2-O-Caffeoyl tartaric acid, (C) 2-O-Feruloyl tartaric
acid, and (D) Salvianolic acid C. Green dashed lines and orange
lines refer to H-bonds and p-interactions, respectively, Illustration
adapted from Sun et al. [21] with the permission of the authors.
(TIF)
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